unknown by Poullis, Michael
al blood product transfusions given as required, was clini-
cally successful.
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Reply to the Editor:
Lemmer raises a number of interesting points with regard
to the removal of abciximab (ReoPro) during cardiopul-
monary bypass with the use of a hemoconcentrator.1
First, as correctly pointed out, the experiments were ini-
tially carried out with normal saline solution, as a proof of
principle. However, as stated in the article, the experiments
were repeated with the use of packed red cells to maintain
clinical relevance. As the free abciximab is biologically
active (Eli Lilly and Company data sheet), then our protocol,
even though simplified, was clinically relevant.
Second, with regard to analyzing native platelet function,
platelet dysfunction after cardiopulmonary bypass occurs for
a myriad of known and unknown preoperative and periopera-
tive reasons, making the evaluation of an intervention diffi-
cult. The aim of this study was to demonstrate a technique to
reduce the inhibition of transfused platelets that occurs as a
result of abciximab inactivation. This should result in a
reduction of postoperative platelet transfusion requirements
and transfusion-related complications, for example, adult res-
piratory distress syndrome. We make no claims to reversal of
the effect of abciximab on native platelets. However, by
implication from our results and the fact that abciximab bind-
ing is known to be a reversible process, hemofiltration will
result in at least a partial reversal of the effect of abciximab
on native platelets.
Third, Lemmer states that the dissociation of abciximab
from platelets is slow, but he then states that abciximab redis-
tribution from native platelets to transfused platelets occurs
immediately after their administration, a kinetics contradic-
tion. Either a platelet-to-platelet interaction occurs (microag-
gregation, which is known not to be the case) or free abcix-
imab is involved. It is this free abciximab that Lemmer quite
rightly implicates in causing transfused platelet dysfunction,
which we demonstrated can be reversed.
Care should be taken with regard to interpretation of per-
centage glycoprotein IIb/IIIa receptor binding as evaluated in
reference 3 provided by Lemmer, since no platelet function
tests were performed, just fluorescence-activated cell sorter
analysis, which does not necessarily correlate with physio-
logic function. The prior administration of aspirin or clopido-
grel, for example, will result in an uninterpretable result in
this situation.
In addition to abciximab (ReoPro), tirofiban (Aggrastat)
and eptifibatide (Integrilin) are also specific glycoprotein
IIb/IIIa inhibitors. The possible reversal of bleeding caused
by glycoprotein IIb/IIIa inhibition therapy via hemofiltration
is now alluded to by the drug information data sheets pro-
duced by Merck, which manufactures Aggrastat, and COR
Therapeutics, Inc, and Key Pharmaceuticals, Inc, which man-
ufacture Integrilin.
Unfortunately, we do not have access to the publication of
Lemmer’s group (in press). It would be interesting to note
what degree of preoperative platelet inhibition was present in
their patients, since it is widely known that abciximab has a
variable clinical effect. Conventional platelet function tests
are impractical in an emergency situation. However, we have
recently demonstrated a quick, simple test of platelet inhibi-
tion caused by abciximab, via the technique of whole blood
microaggregation, which involved the use of a standard labo-
ratory Coulter counter (Coulter Electronics, Inc, Hialeah,
Fla).3 This should aid in assessing preoperative platelet inhi-
bition, thus making it possible to rank patients by their sus-
ceptibility to bleeding, so that accurate evaluation of any
antibleeding strategy can be ascertained.
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